SXTP (60 Degrees Pharmaceuticals) Long-Term Debt: $0.14 Mil (As of Mar. 2026)


SXTP 60 Degrees Pharmaceuticals Inc SXTP
44 GF Score
Price $1.75
GF Value $2.05
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is 60 Degrees Pharmaceuticals Long-Term Debt?

60 Degrees Pharmaceuticals SXTP -2.29% 44 Long-Term Debt is $0.14 Mil as of Mar. 2026. GuruFocus rates SXTP with a GF Score™ of 44/100 and a GF Value™ of $2.05 (Modestly Undervalued). The stock has 5 warning signs investors should review.

60 Degrees Pharmaceuticals's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.14 Mil.

60 Degrees Pharmaceuticals's quarterly Long-Term Debt declined from Sep. 2025 ($0.15 Mil) to Dec. 2025 ($0.14 Mil) and declined from Dec. 2025 ($0.14 Mil) to Mar. 2026 ($0.14 Mil).

60 Degrees Pharmaceuticals's annual Long-Term Debt declined from Dec. 2023 ($0.15 Mil) to Dec. 2024 ($0.15 Mil) and declined from Dec. 2024 ($0.15 Mil) to Dec. 2025 ($0.14 Mil).

60 Degrees Pharmaceuticals  (NAS:SXTP) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

60 Degrees Pharmaceuticals Long-Term Debt Related Terms

60 Degrees Pharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for 60 Degrees Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

60 Degrees Pharmaceuticals Long-Term Debt Chart

60 Degrees Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 18.75 1.27 0.15 0.15 0.14

60 Degrees Pharmaceuticals Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.15 0.15 0.14 0.14
SXTP
44GF Score
60 Degrees Pharmaceuticals Inc SXTP
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.14 Mil mean?
60 Degrees Pharmaceuticals (SXTP) has a Long-Term Debt of $0.14 Mil as of Mar. 2026.
Is 60 Degrees Pharmaceuticals' Long-Term Debt too high?
60 Degrees Pharmaceuticals' current Long-Term Debt is $0.14 Mil. Overall, 60 Degrees Pharmaceuticals has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 60 Degrees Pharmaceuticals' Long-Term Debt compare to GLMD and FBLG?
60 Degrees Pharmaceuticals' Long-Term Debt of $0.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. 60 Degrees Pharmaceuticals's current Long-Term Debt is $0.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 60 Degrees Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals (SXTP) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.05, compared to a current price of $1.75 — trading 14.6% below its estimated fair value. The current Long-Term Debt is $0.14 Mil. 60 Degrees Pharmaceuticals' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For 60 Degrees Pharmaceuticals (SXTP), the current Long-Term Debt is $0.14 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 60 Degrees Pharmaceuticals (SXTP) Overvalued in 2026?

Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals stock appears to be undervalued. The current stock price of $1.75 is trading 14.6% below its estimated GF Value™ of $2.05. GuruFocus considers 60 Degrees Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for SXTP:

  • Long-Term Debt: $0.14 Mil
  • GF Value™: $2.05 vs. price of $1.75 (14.6% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the SXTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

60 Degrees Pharmaceuticals Business Description

Address 1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
44GF Score

Get the complete analysis for SXTP

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.75
Price
$2.05
GF Value